Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

Triple negative breast cancer (TNBC) is an aggressive subset for which effective therapeutic approaches are needed. A significant proportion of TNBC patients harbor either germline or somatic mutations in BRCA1, or epigenetic silencing of BRCA1, which renders them deficient in DNA repair. Virtually...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:NPJ Breast Cancer
Main Authors: Na, Bing, Yu, Xin, Withers, Tracy, Gilleran, John, Yao, Ming, Foo, Tzeh Keong, Chen, Chunxia, Moore, Dirk, Lin, Yong, Kimball, S. David, Xia, Bing, Ganesan, Shridar, Carpizo, Darren R.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6465291/
https://ncbi.nlm.nih.gov/pubmed/30993195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-019-0110-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados